Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial

Lancet

Volumn 367, Issue 9513, 2006, Pages 825-831

  Palumbo, Antonio ^a   Bringhen, Sara ^a   Caravita, Tommaso ^b   Merla, Emanuela ^c   Capparella, Vincenzo ^e   Callea, Vincenzo ^f   Cangialosi, Clotilde ^g   Grasso, Mariella ^h   Rossini, Fausto ⁱ   Galli, Monica ^j   Catalano, Lucio ^k   Zamagni, Elena ^l   Petrucci, Maria Teresa ^m   De Stefano, Valerio ⁿ   Ceccarelli, Manuela ^o   Ambrosini, Maria Teresa ^a   Avonto, Ilaria ^a   Falco, Patrizia ^a   Ciccone, Giovannino ^o   Liberati, Anna Marina ^p   Musto, Pellegrino ^d   Boccadoro, Mario ^a   more..

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^d Centro di Riferimento Oncologico Basilicata   (Italy)

^e SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

^f BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^g VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^h S CROCE E CARLE HOSPITAL   (Italy)

ⁱ AO San Gerardo   (Italy)

^j OSPEDALI RIUNITI   (Italy)

^k UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^l UNIVERSITY OF BOLOGNA   (Italy)

^m SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁿ CATHOLIC UNIVERSITY   (Italy)

^o MOLINETTE HOSPITAL   (Italy)

^p POLICLINICO MONTELUCE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ENOXAPARIN; MELPHALAN; PREDNISONE; THALIDOMIDE;

ACUTE HEART INFARCTION; ADULT; AGED; ANEMIA; ANGINA PECTORIS; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; EDEMA; FATIGUE; FEMALE; HEART FAILURE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HERPES ZOSTER; HUMAN; HYPERTENSION; KIDNEY DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE MYELOMA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TOXIC EPIDERMAL NECROLYSIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 33644843725     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68338-4     Document Type: Article

References (36)

1. J Ferlay, F Bray, P Pisani, DM Parkin GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase No 5 version 2.0 2004 IARCPress Lyon
2. M Attal, JL Harousseau, AM Stoppa A prospective, randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma N Engl J Med 335 1996 91 97
3. JA Child, GJ Morgan, FE Davies High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N Engl J Med 348 2003 1875 1883
4. A Palumbo, S Bringhen, MT Petrucci Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomised trial Blood 104 2004 3052 3057
5. Myeloma Trialist' Collaborative Group Combination chemotherapy versus melphalan and prednisone as treatment of multiple myeloma: an overview of 6,633 patients from 27 randomised trials J Clin Oncol 16 1998 3832 3842
6. M Boccadoro, F Marmont, M Tribalto Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients J Clin Oncol 9 1991 444 448
7. B Durie, R Kyle, A Belch Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation Hematol J 4 2003 379 398
8. RA Kyle, V Rajkumar Multiple myeloma N Engl J Med 351 2004 1860 1873
9. RJ D'Amato, MS Loughnan, E Flynn, J Folkman Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci USA 91 1994 4082 4085
10. BE Turk, H Jiang, JO Liu Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production Proc Natl Acad Sci USA 93 1996 7552 7556
11. H Geitz, S Handt, K Zwingenberger Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade Immunopharmacology 31 1996 213 221
12. S Singhal, J Metha, R Desikan Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 1999 1565 1571
13. P Tosi, E Zamagni, C Cellini Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma Haematologica 87 2002 408 412
14. I Yakoub-Agha, M Attal, C Dumontet Thalidomide in patients with advanced multiple myeloma: a study of 83 patients - report of the Intergroupe Francophone du Myelome (IFM) Hematol J 3 2002 185 192
15. D Weber, K Rankin, M Gavino, K Delasalle, R Alexanian Thalidomide alone or with dexamethasone for previously untreated multiple myeloma J Clin Oncol 21 2003 16 19
16. A Palumbo, A Bertola, P Falco Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma Hematol J 5 2004 318 324
17. TM Moehler, K Neben, A Benner Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy Blood 98 2001 3846 3848
18. MH Kropff, N Lang, G Bisping Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCTD) in primary refractory or relapsed multiple myeloma Br J Haematol 122 2003 607 616
19. R Garcia-Sanz, MI Gonzalez-Fraile, JM Hernandez The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma Leukemia 18 2004 856 863
20. A Palumbo, A Bertola, P Musto Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma Cancer 104 2005 1428 1433
21. IM Ghobrial, SV Rajkumar Management of thalidomide toxicity J Supportive Oncol 1 2003 194 205
22. K Osman, R Comenzo, SV Rajkumar Deep venous thrombosis and thalidomide therapy for multiple myeloma N Engl J Med 344 2001 1951 1952
23. M Zangari, E Siegel, B Barlogie Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy Blood 100 2002 1168 1171
24. M Zangari, B Barlogie, E Anaissie Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation Br J Haematol 26 2004 715 721
25. M Cavo, E Zamagni, P Tosi Superiority of thalidomide and dexamethasone over vincristine-doxorubicin dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma Blood 106 2005 35 39
26. M Offidani, L Corvatta, M Marconi Common and rare side-effects of low dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy Eur J Haematol 72 2004 403 409
27. P Tosi, E Zamagni, C Cellini Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma Eur J Haematol 74 2005 212 216
28. JB Zeldis, BA Williams, SD Thomas, ME Elsayed S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide Clin Ther 21 1999 319 330
29. J Blade, D Samson, D Reece on behalf of the Myeloma Subcommittee of the EBMT (European Group for Blood and Marrow Transplant) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation Br J Haematol 102 1998 1115 1123
30. EL Kaplan, P Meier Non parametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
31. D Dingli, SV Rajkumar, GS Nowakowski Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial Haematologica 90 2005 1650 1654
32. K Zervas, A Dimopoulos, E Hatzicharissi Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study Ann Oncol 15 2004 134 138
33. 2 (MEL100) for newly diagnosed mieloma patients aged 65-75 years. Interim analysis of the IFM 99-06 trial on 350 patients Blood 104 2004 206 (abstr)
34. MM Samama, AT Cohen, JY Darmon for the Prophylaxis in Medical Patients with Enoxaparin Study Group A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients N Engl J Med 341 1999 793 800
35. P Prandoni, A Falanga, A Piccioli Cancer and venous thromboembolism Lancet Oncol 6 2005 401 410
36. BG Durie Low-dose thalidomide in myeloma: efficacy and biologic significance Semin Oncol 29 2002 34 38